New drug could ease endometriosis pain in major trial
NCT ID NCT06076486
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 3 trial tested the drug elagolix in 202 women with moderate to severe pain from endometriosis. Participants took either elagolix or a placebo for 12 weeks. The study measured how well the drug reduced menstrual cramps and pelvic pain. The goal is to see if elagolix can provide a new treatment option for this painful condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Elagolix
- What this could lead to
- If successful, elagolix could offer a new non-surgical option to reduce painful periods and pelvic pain in women with endometriosis.
- What could go wrong
- This is a completed phase 3 trial, but results are not yet published. The drug may not work for everyone, and side effects are possible. It aims to manage symptoms, not cure the condition.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University First Hospital
Beijing, Beijing Municipality, 100034, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can yoga ease the pain of endometriosis after surgery?
- Building a biological treasure trove to decode Women's health mysteries
- Gaming for health: could a video game empower endometriosis patients?
- Can a new formulation of an endometriosis drug match the standard?
- Can a glowing dye reveal a Woman's fertility after ovarian cyst surgery?
- Can we predict endometriosis recurrence and fertility outcomes?